Influence of treatment with intravenous CYC on cytological analysis of BALF
| All patients (n = 20) | Neutrophilic alveolitis (n = 12) | Without neutrophilic alveolitis (n = 8) | ||||
|---|---|---|---|---|---|---|
| Before CYC | After CYC | Before CYC | After CYC | Before CYC | After CYC | |
| All values are expressed as median (range). | ||||||
| *p<0.05 v patients with NA before CYC (Mann Whitney U test); †p<0.05 v total group of patients before CYC; ‡p<0.05 v patients with NA before CYC (Wilcoxon matched pairs test). | ||||||
| CYC, cyclophosphamide; NA, neutrophilic alveolitis. | ||||||
| BAL recovery (%) | 51.0 (40.0–67.0) | 52.0 (40.0–70.0) | 52 (40.0–63.0) | 55.0 (40.0–66.0) | 49.0 (41.0–67.0) | 50.0 (40.0–70.0) |
| Total cell count (×104/ml) | 25.0 (10.0–100.0) | 20.0† (10.0–50.0) | 25.0 (10.0–100.0) | 20.5 (10.0–45.0) | 25.0 (15.0–80.0) | 20.0 (10.0–50.0) |
| Neutrophils (%) | 5.0 (1.0–19.0) | 3.0 (1.0–13.0) | 10.0 (4.0–19.0) | 4.5‡ (2.0–13.0) | 2.0* (1.0–3.0) | 2.0 (1.0–4.0) |
| Lymphocytes (%) | 19.0 (8.0–53.0) | 20.0 (8.0–50.0) | 16.0 (9.0–38.0) | 19.0 (8.0–53.0) | 26.0 (8.0–53.0) | 23.5 (15.0–39.0) |
| Eosinophils (%) | 0.5 (0.0–5.0) | 0.0 (0.0–1.0) | 1.1 (0.0–5.0) | 0.0‡ (0.0–1.0) | 0.0* (0.0.–1.0) | 0.0 (0.0–1.0) |
| Macrophages (%) | 71.0 (45.0–90.0) | 75.0 (70.0–86.0) | 69.5 (46.0–84.0) | 73.0 (44.0–86.0) | 74.0 (45.0–90.0) | 73.5 (58.0–83.0) |